Norditropin is named as a drug or biological intervention in 3 clinical trials in our Ireland, UK, USA, India and China trial registers, 1 of which is recruiting. Lead sponsors include Novo Nordisk A/S (2) and Changchun GeneScience Pharmaceutical Co., Ltd. (1). Registered phases: Phase 2, Phase 3 and Phase 1. Conditions studied include Short Stature Children Born Small for Gestational Age (SGA); SGA, Turner Syndrome, Noonan Syndrome, ISS; Safety.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07016802 | A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) (ClinicalTrials.gov ↗) Safety, Tolerability, Adult Growth Hormone Deficiency |
Phase 1 | Recruiting |
| NCT05330325 | A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow (ClinicalTrials.gov ↗) SGA, Turner Syndrome, Noonan Syndrome, ISS |
Phase 3 | Active, closed |
| NCT03878446 | A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day Short Stature Children Born Small for Gestational Age (SGA) |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Short Stature Children Born Small for Gestational Age (SGA) | 1 |
| SGA, Turner Syndrome, Noonan Syndrome, ISS | 1 |
| Safety | 1 |
| Tolerability | 1 |
| Adult Growth Hormone Deficiency | 1 |
| Lead sponsor | Trials |
|---|---|
| Novo Nordisk A/S | 2 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 1 |
| Register | Norditropin trials |
|---|---|
| Clinical trials in Ireland | 2 |
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in India | 2 |
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Norditropin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Norditropin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.